Skip to main content

Advertisement

Log in

Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia

International Journal of Hematology Aims and scope Submit manuscript

Abstract

MicroRNAs (miRNAs) are a type of small non-coding RNA molecule that play important roles in tumor initiation, chemotherapy response, promotion, and progression by negatively interfering with gene expression. The aim of the present study was to investigate the serum expression status and explore the prognostic significance of miR-10a-5p in acute myeloid leukemia (AML). The serum expression level of miR-10a-5p in de novo AML was significantly higher, compared with that in controls. The area under the receiver operator characteristic (ROC) curve was of 0.831 in the diagnostic value of miR-10a-5p. In the complete remission (CR) group, the serum expression level of miR-10a-5p was similar to that of healthy subjects and demonstrated a significant downtrend when compared to that on the day of diagnosis. Nevertheless, miR-10a-5p expression was found to significantly increase in cases of relapsed AML when compared individually to the CR population. On analysis of the association of miR-10a-5p expression with the clinical characteristics at diagnosis in AML patients, lower CR rates occurred more frequently in the high-expression group. In addition, high miR-10a-5p expression was associated with poorer overall survival (OS). These data suggest that miR-10a-5p may serve as a biomarker useful to improving the management of AML patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 2013;88(4):318–27.

    Article  CAS  PubMed  Google Scholar 

  2. Estey E. Dohner H., Acute myeloid leukaemia. Lancet. 2006;368(9550):1894–907.

    Article  PubMed  Google Scholar 

  3. Zhu YD, Wang L, Sun C, et al. Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia. Med Oncol. 2012;29(4):2323–31.

    Article  CAS  PubMed  Google Scholar 

  4. Osada H. Takahashi T., MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2007;28(1):2–12.

    Article  CAS  PubMed  Google Scholar 

  5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.

    Article  CAS  PubMed  Google Scholar 

  6. Lujambio A. Lowe S. W., The microcosmos of cancer. Nature. 2012;482(7385):347–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer. 2003;3(4):243–52.

    Article  CAS  PubMed  Google Scholar 

  8. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008;3(9):e3148.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105(30):10513–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Debernardi S, Skoulakis S, Molloy G, et al. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia. 2007;21(5):912–6.

    CAS  PubMed  Google Scholar 

  11. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.

    Article  CAS  PubMed  Google Scholar 

  12. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58 (10):1375-1381.

  13. Ovcharenko D, Stolzel F, Poitz D, et al. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. Exp Hematol 2011;39 (10):1030–1042 (e1037).

  14. Bryant A, Palma CA, Jayaswal V, et al. miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death. Mol Cancer. 2012;11:8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Zhi F, Cao X, Xie X, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS ONE. 2013;8(2):e56718.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Cull EH, Altman JK. Contemporary treatment of APL. Curr Hematol Malig Rep 2014;9 (2):193–201.

  17. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642–9.

    Article  PubMed  Google Scholar 

  18. Fayyad-Kazan H, Bitar N, Najar M, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med. 2013;11:31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Nonaka R, Nishimura J, Kagawa Y, et al. Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. Oncol Rep. 2014;32(6):2354–8.

    CAS  PubMed  Google Scholar 

  20. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012;32(2):326–48.

    Article  PubMed  Google Scholar 

  22. Tallman MS, Gilliland DG, Rowe JM, et al. Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154–63.

    Article  CAS  PubMed  Google Scholar 

  23. Ganetsky A. The role of decitabine for the treatment of acute myeloid leukemia. Ann Pharmacother. 2012;46(11):1511–7.

    Article  PubMed  Google Scholar 

  24. Mansfield JH, Harfe BD, Nissen R, et al. MicroRNA-responsive ‘sensor’ transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression. Nat Genet. 2004;36(10):1079–83.

    Article  CAS  PubMed  Google Scholar 

  25. Lund AH. miR-10 in development and cancer. Cell Death Differ. 2010;17(2):209–14.

    Article  CAS  PubMed  Google Scholar 

  26. Long MJ, Wu FX, Li P, et al. MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett. 2012;324(2):186–96.

    Article  CAS  PubMed  Google Scholar 

  27. Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34 + cells increases USF2-mediated cell growth. Mol Cancer Res. 2008;6(12):1830–40.

    Article  CAS  PubMed  Google Scholar 

  28. Jia H, Zhang Z, Zou D, et al. MicroRNA-10a is down-regulated by DNA methylation and functions as a tumor suppressor in gastric cancer cells. PLoS ONE. 2014;9(1):e88057.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc + AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106(3):899–902.

    Article  CAS  PubMed  Google Scholar 

  30. Havelange V, Ranganathan P, Geyer S, et al. Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood. 2014;123(15):2412–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Chen CZ, Li L, Lodish HF, et al. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654):83–6.

    Article  CAS  PubMed  Google Scholar 

  32. Lutherborrow M, Bryant A, Jayaswal V, et al. Expression profiling of cytogenetically normal acute myeloid leukemia identifies microRNAs that target genes involved in monocytic differentiation. Am J Hematol. 2011;86(1):2–11.

    Article  CAS  PubMed  Google Scholar 

  33. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115–36.

    Article  PubMed  Google Scholar 

  34. Li X, Xu F, Chang C, et al. Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes. Haematologica. 2013;98(3):414–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids–the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Sun W, Ma Y, Chen P, et al. MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-beta/Smad2/STAT3/STAT5 pathway. Mol Med Rep 2015;11(5):3854–9.

    Google Scholar 

  37. Rushworth SA, Murray MY, Barrera LN, et al. Understanding the role of miRNA in regulating NF-kappaB in blood cancer. Am. J Cancer Res. 2012;2(1):65–74.

    CAS  Google Scholar 

  38. Perez-Rivas LG, Jerez JM, Carmona R, et al. A microRNA signature associated with early recurrence in breast cancer. PLoS ONE. 2014;9(3):e91884.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Li Z, Zhao J, Li Q, et al. KLF4 promotes hydrogen-peroxide-induced apoptosis of chronic myeloid leukemia cells involving the bcl-2/bax pathway. Cell Stress Chaperones. 2010;15(6):905–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Peng C, Chen Y, Li D, et al, Role of Pten in leukemia stem cells. Oncotarget 2010;1 (2):156–160.

  41. LaBelle JL, Katz SG, Bird GH, et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest. 2012;122(6):2018–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was financially supported by National Natural Science Foundation of China (NSFC, 81300422).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Feng Zhi or Yan Liu.

Ethics declarations

Conflict of interest

None of the authors has any potential financial interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhi, Y., Xie, X., Wang, R. et al. Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. Int J Hematol 102, 296–303 (2015). https://doi.org/10.1007/s12185-015-1829-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-015-1829-6

Keywords

Navigation